Back to Search Start Over

PCN126 A Cost IMPACT Analysis of Clonoseq® As a Valid and CE-Certified Minimal Residual Disease (MRD) Diagnostic in Multiple Myeloma in Germany.

Authors :
Walzer, S.
Vollmer, L.
Krenberger, S.
Rosseel, F.
Hewitt, T.
Eckert, B.
Source :
Value in Health. 2020 Supplement 2, Vol. 23, pS445-S445. 1p.
Publication Year :
2020

Subjects

Subjects :
*MULTIPLE myeloma
*COST analysis

Details

Language :
English
ISSN :
10983015
Volume :
23
Database :
Academic Search Index
Journal :
Value in Health
Publication Type :
Academic Journal
Accession number :
160979881
Full Text :
https://doi.org/10.1016/j.jval.2020.08.263
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details